Supernus Pharmaceuticals, Inc. has officially announced the removal of its common stock from the Nasdaq Stock Market. This decision, filed on November 2, 2026, indicates a significant shift in the company’s public trading status.

The filing, identified by accession number 0001354457-26-001045, highlights that the removal is in accordance with the relevant regulations. The company has been navigating a competitive landscape within the pharmaceutical preparations sector, which is classified under SIC code 2834.

Background

Supernus Pharmaceuticals, Inc. is a company focused on developing and commercializing innovative products for the treatment of central nervous system diseases. The company is incorporated in Delaware and is classified as a large accelerated filer. Its common stock trades under the ticker symbol SUPN on the Nasdaq exchange.

What the Filing Says

The filing states, "Notification of Removal" under the relevant rule provision, indicating that Supernus Pharmaceuticals has decided to delist its common stock from Nasdaq. The document was signed by Jennifer Fainer, CDO Analyst, on the same day of the filing.

Impact

This delisting may affect various stakeholders, including investors and employees who hold stock options. The decision reflects a broader trend in the pharmaceutical industry, where companies are reassessing their public market strategies.

What's Next

The filing does not say what happens next.